Wadha Aldossary, Nada Alqahtani, Layla Asiri, Noora Alkhurayef, Samar Alagl, Sana Alturki, Duha Saad, Mashael Al Yahya, Samah Al-Harthi
{"title":"Advances and applications of engineered protein therapeutics and their role in precision medicine.","authors":"Wadha Aldossary, Nada Alqahtani, Layla Asiri, Noora Alkhurayef, Samar Alagl, Sana Alturki, Duha Saad, Mashael Al Yahya, Samah Al-Harthi","doi":"10.3389/fbioe.2026.1857362","DOIUrl":null,"url":null,"abstract":"<p><p>Proteins are a vital class of biomolecules. They play essential roles in biological processes, including building cellular structures, forming cellular channels and receptors, catalyzing biological reactions, transporting molecules, and contributing to immune defense mechanisms. Advances in protein engineering have enabled the genetic modification of naturally occurring proteins, using recombinant deoxyribonucleic acid (DNA) technology, leading to the development of therapeutic proteins with enhanced specificity, stability, and clinical performance. Despite the rapid growth of engineered biologics, a comprehensive understanding of how these innovations intersect with precision medicine remains limited. This review addresses this gap by summarizing the major contemporary approaches used in therapeutic protein engineering, including directed evolution, rational design, and <i>de novo</i> protein design, and by analyzing their roles in enabling patient-tailored interventions. It provides an integrated overview of the clinical applications of engineered therapeutic proteins across key medical fields, supported by a list of U.S. Food and Drug Administration- and European Medicines Agency-approved protein therapeutics from 2020 to 2025. The review further provides a comparative perspective on major protein engineering strategies, highlighting their relative advantages and limitations, while examining differences in clinical translation across major disease areas. By combining technological advances with disease-specific applications, this review offers a perspective that has not been fully developed in the literature. Finally, the review discusses the current challenges affecting the implementation of precision medicine, including immunogenicity, regulatory constraints, and ethical considerations, and outlines future directions, such as artificial intelligence-guided protein design, targeted protein degradation, and personalized vaccine development. Collectively, these insights highlight the expanding role of engineered proteins in shaping the next-generation of precision therapeutics and emphasize the growing importance of integrating multidisciplinary approaches to advance therapeutic innovation in modern clinical practice.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"14 ","pages":"1857362"},"PeriodicalIF":5.8000,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13678489/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2026.1857362","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Proteins are a vital class of biomolecules. They play essential roles in biological processes, including building cellular structures, forming cellular channels and receptors, catalyzing biological reactions, transporting molecules, and contributing to immune defense mechanisms. Advances in protein engineering have enabled the genetic modification of naturally occurring proteins, using recombinant deoxyribonucleic acid (DNA) technology, leading to the development of therapeutic proteins with enhanced specificity, stability, and clinical performance. Despite the rapid growth of engineered biologics, a comprehensive understanding of how these innovations intersect with precision medicine remains limited. This review addresses this gap by summarizing the major contemporary approaches used in therapeutic protein engineering, including directed evolution, rational design, and de novo protein design, and by analyzing their roles in enabling patient-tailored interventions. It provides an integrated overview of the clinical applications of engineered therapeutic proteins across key medical fields, supported by a list of U.S. Food and Drug Administration- and European Medicines Agency-approved protein therapeutics from 2020 to 2025. The review further provides a comparative perspective on major protein engineering strategies, highlighting their relative advantages and limitations, while examining differences in clinical translation across major disease areas. By combining technological advances with disease-specific applications, this review offers a perspective that has not been fully developed in the literature. Finally, the review discusses the current challenges affecting the implementation of precision medicine, including immunogenicity, regulatory constraints, and ethical considerations, and outlines future directions, such as artificial intelligence-guided protein design, targeted protein degradation, and personalized vaccine development. Collectively, these insights highlight the expanding role of engineered proteins in shaping the next-generation of precision therapeutics and emphasize the growing importance of integrating multidisciplinary approaches to advance therapeutic innovation in modern clinical practice.
期刊介绍:
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.